Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer Discovery Analysis Demonstrates Transformative Sensitivity of 95% ...

achieving 95% sensitivity and 98% specificity for pancreatic cancer detection. Mainz Biomed N.V. has announced an exclusive licensing agreement with Liquid Biosciences to access a portfolio of ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...

(MENAFN- GlobeNewsWire - Nasdaq) Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement ...